Phototherapy for scleroderma: Biologic rationale, results, and promise

Current Opinion in Rheumatology

Volumn 14, Issue 6, 2002, Pages 723-726

  Fisher, Gary J ^a,b   Kang, Sewon ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN SYNTHESIS; CONNECTIVE TISSUE DISEASE; HUMAN; MORBIDITY; PHOTOTHERAPY; PRIORITY JOURNAL; REVIEW; SCLERODERMA; SKIN; SYSTEMIC SCLEROSIS; ULTRAVIOLET A RADIATION;

HUMANS; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; ULTRAVIOLET RAYS; ULTRAVIOLET THERAPY;

EID: 0036838771     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200211000-00016     Document Type: Review

References (32)

1. 1 phototherapy. Lancet 1995, 346:1166.
2. Gruss C, Stucker M, Kobyletzki G, et al.: Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood. Br J Dermatol 1997, 136:293-294.
3. Gruss C, Reed J, Altmeyer P, et al.: Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet 1997, 350:1295-1296.
4. 1 radiation therapy for localized scleroderma. J Am Acad Dermatol 1997, 36:938-944.
5. 1 phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 1998, 38:21-26.
6. Gruss CJ, Von Kobyletzki G, Behrens-Williams SC, et al.: Effects of low dose ultraviolet A-1 phototherapy on morphea. Photodermatol Photoimmunol Photomed 2001, 17:149-155.
7. Kreuter A, Gambichler T, Avermaete A, et al.: Combined treatment with calcipotriol ointment and low dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol 2001, 18:241-245.
8. Camacho NR, Sanchez JE, Martin RF, et al.: Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J Am Acad Dermatol 2001, 45:697-699.
9. Morita A, Kobayashi K, Isomura I, et al.: Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000, 43:670-674.
10. Morita A, Sakakibara S, Sakakibara N, et al.: Successful treatment of systemic sclerosis with topical PUVA. J Rheumatol 1995, 22:2361-2365.
11. Kerscher M, Meurer M, Sander C, et al.: PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients. Arch Dermatol 1996, 132:1280-1282.
12. Kanekura T, Fukumaru S, Matsushita S, et al.: Successful treatment of scleroderma with PUVA therapy. J Dermatol 1996, 23:455-459.
13. Grundmann-Kollmann M, Ochsendorf F, Zollner TM, et al.: PUVA-cream phototherapy for the treatment of localized scleroderma. J Am Acad Dermatol 2000, 43:675-678.
14. El-Mofty M, Zaher H, Bosseila M, et al.: Low-dose broad band UVA in morphea using a new method for evaluation. Photodermatol Photoimmunol Photomed 2000, 16:43-49.
15. Morison WL: Psoralen UVA therapy for linear and generalized morphea. J Am Acad Dermatol 1997, 37:657-659.
16. Oikarinen A, Knuutinen A: Ultraviolet A sunbed used for the treatment of scleroderma. Acta Derm Venereol 2001, 81:432-423.
17. Steger JW, Matthews JH: UVA therapy for scleroderma. J Am Acad Dermatol 1999, 40:787-788.
18. Ullrich S: Photoimmune suppression and photocarcinogenesis. Front Biosci 2002, 7:d684-d703.
19. Cooper K: Cell-mediated immunosuppressive mechanisms induced by UV radiation. Photochem Photobiol 1996, 63:400-406.
20. Von Kobyletzki G, Heine O, Stephan H, et al.: UVA1 irradiation induces deoxyribonuclease dependent apoptosis in cutaneous T-cell lymphoma in vivo. Photodermatol Photoimmunol Photomed 2000, 16:271-277.
21. Breuckmann F, Pieck C, Kreuter A, et al.: Opposing effects of UVA1 phototherapy on the expression of bcl-2 and p53 in atopic dermatitis. Arch Dermatol Res 2001, 293:178-183.
22. Hill L, Shreedhar V, Kripke M, et al.: A critical role of Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation. J Exp Med 1999, 189:1289-1294.
23. Fisher GJ, Voorhees JJ: Molecular mechanisms of photoaging and its prevention by retinoic acid: ultraviolet irradiation induces MAP kinase signal transduction cascades that induce Ap-1-regulated matrix metalloproteinases that degrade human skin in vivo. J Investig Dermatol Symp Proc 1998, 3:61-68.
24. Fisher GJ, Wang ZQ, Datta SC, et al.: Pathophysiology of premature skin aging induced by ultraviolet light. N Engl J Med 1997, 337:1419-1428.
25. Fisher GJ, Datta SC, Talwar HS, et al.: Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature 1996, 379:335-339.
26. Fisher GJ, Talwar HS, Lin J, et al.: Retinoic acid inhibits induction of c-Jun protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo. J Clin Invest 1998, 101:1432-1440.
27. Talwar HS, Griffiths CE, Fisher GJ, et al.: Reduced type I and type III procollagens in photodamaged adult human skin. J Invest Dermatol 1995, 105:285-290.
28. Ghosh AK, Yuan W, Mori Y, et al.: Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene 2000, 19:3546-3555.
29. Chung KY, Agarwal A, Uitto J,et al.: An AP-1 binding sequence is essential for regulation of the human alpha2(I) collagen (COL1A2) promoter activity by transforming growth factor-beta. J Biol Chem 1996, 271:3272-3278.
30. Chen SJ, Yuan W, Lo S, et al.: Interaction of Smad3 with a proximal Smadbinding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta. J Cell Physiol 2000, 183:381-392.
31. Verrecchia F, Vindevoghel L, Lechleider RJ, et al.: Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner. Oncogene 2001, 20:3332-3340.
32. Dennler S, Prunier C, Ferrand N, et al.: c-Jun inhibits transforming growth factor beta-mediated transcription by repressing Smad3 transcriptional activity. J Biol Chem 2000, 275:28858-28865.